Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Fortis Therapeutics Closes $40M Series A

2021-03-29
SAN DIEGO, CA, Fortis Therapeutics, an immuno-oncology biotech, announced the close of a $40 million Series A financing.
Fortis Therapeutics, an immuno-oncology biotech, announced the close of a $40 million Series A financing. Participating in this financing are existing investors Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital; as well as new investors the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation (MMRF), and Prostate Cancer Foundation (PCF).

Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors